Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The U.S. Food and Drug Administration (FDA) will hold a public meeting of its Endocrinologic and Metabolic Drugs Advisory Committee to discuss the safety and efficacy of new drug application (NDA) 22–505, tesamorelin acetate (EGRIFTA®) sterile lyophilized powder for injection, by Theratechnologies, Inc.

FDA Notifications